Scopus BioPharma

Scopus BioPharma is a private, pre-revenue biotech leveraging strategic academic partnerships to advance a pipeline of RNA and gene therapies. The company's core strategy involves in-licensing and co-developing ground-breaking discoveries from premier institutions like City of Hope, the NIH, and Hebrew University. Its most advanced asset is a targeted immuno-oncology gene therapy for cancer, positioning it in the competitive but high-potential field of next-generation oncology treatments. Leadership combines financial expertise from healthcare-focused investment firm HCFP with scientific guidance from an experienced advisory board.

Partnership-driven model to in-license and co-develop RNA and gene therapy discoveries from academic institutions (City of Hope, NIH, Hebrew University).

Operates in the highly competitive fields of immuno-oncology and gene therapy, competing against large pharmaceutical companies, well-funded biotechs, and other academic spin-outs. Success will require demonstrating differentiated efficacy, safety, or a novel mechanism.